Inavolisib for metastatic castration-resistant prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called Inavolisib for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of prostate cancer called adenocarcinoma, which has spread and is no longer controlled by standard hormone therapy.
- You have had only one prior treatment with a newer hormone therapy like abiraterone or enzalutamide.
- You have a tumor sample available for testing to see if your cancer has certain genetic changes.
- Your blood sugar levels are normal (fasting glucose below 100 mg/dL and HbA1c below 5.7%).
- You have not had any prior treatment with drugs that target the PI3K/AKT/mTOR pathway.
- You do not have liver metastases or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a targeted drug called Inavolisib in people whose pancreatic cancer has worsened after earlier chemotherapy. The goal is to see if it can slow the cancer and what side effects might occur.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.